These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3550516)

  • 1. Brain grafting as a treatment for Parkinson's disease.
    Perlow MJ
    Neurosurgery; 1987 Feb; 20(2):335-42. PubMed ID: 3550516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation of monoamine-producing cell systems in oculo and intracranially: experiments in search of a treatment for Parkinson's Disease.
    Olson L; Backlund EO; Freed W; Herrera-Marschitz M; Hoffer B; Seiger A; Strömberg I
    Ann N Y Acad Sci; 1985; 457():105-26. PubMed ID: 3913358
    [No Abstract]   [Full Text] [Related]  

  • 3. Transplants in Parkinson's disease.
    Lindvall O
    Eur Neurol; 1991; 31 Suppl 1():17-27. PubMed ID: 1855521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery.
    Kordower JH; Goetz CG; Freeman TB; Olanow CW
    Exp Neurol; 1997 Mar; 144(1):41-6. PubMed ID: 9126150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for the treatment of Parkinson's disease using neural grafts.
    Barker RA
    Expert Opin Pharmacother; 2000 Jul; 1(5):889-902. PubMed ID: 11249498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathology of fetal nigra transplants for Parkinson's disease.
    Kordower JH; Sortwell CE
    Prog Brain Res; 2000; 127():333-44. PubMed ID: 11142034
    [No Abstract]   [Full Text] [Related]  

  • 7. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.
    Mendez I; Sanchez-Pernaute R; Cooper O; Viñuela A; Ferrari D; Björklund L; Dagher A; Isacson O
    Brain; 2005 Jul; 128(Pt 7):1498-510. PubMed ID: 15872020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a neural transplantation therapy for Parkinson's disease: experimental principles from animal studies.
    Dunnett SB
    Acta Neurochir Suppl (Wien); 1991; 52():35-8. PubMed ID: 1792963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fetal nigral transplantation as a therapy for Parkinson's disease.
    Olanow CW; Kordower JH; Freeman TB
    Trends Neurosci; 1996 Mar; 19(3):102-9. PubMed ID: 9054056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell treatment for Parkinson's disease: an update for 2005.
    Snyder BJ; Olanow CW
    Curr Opin Neurol; 2005 Aug; 18(4):376-85. PubMed ID: 16003112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials.
    Lindvall O; Björklund A
    Acta Neurol Scand Suppl; 1989; 126():197-210. PubMed ID: 2694732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
    Collier TJ; Sortwell CE; Elsworth JD; Taylor JR; Roth RH; Sladek JR; Redmond DE
    J Comp Neurol; 2002 Jan; 442(4):320-30. PubMed ID: 11793337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.
    Piccini P; Brooks DJ; Björklund A; Gunn RN; Grasby PM; Rimoldi O; Brundin P; Hagell P; Rehncrona S; Widner H; Lindvall O
    Nat Neurosci; 1999 Dec; 2(12):1137-40. PubMed ID: 10570493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
    Bentlage C; Nikkhah G; Cunningham MG; Björklund A
    Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurotransplantation. III. Intracerebral grafting of fetal substantia nigra in Parkinson's disease].
    Dymecki J; Zabek M; Mazurowski W; Lechowicz W
    Neurol Neurochir Pol; 1994; 28(1):73-86. PubMed ID: 8028708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repairing the brain in Parkinson's disease: where next?
    Barker RA
    Mov Disord; 2002 Mar; 17(2):233-41. PubMed ID: 11921107
    [No Abstract]   [Full Text] [Related]  

  • 19. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease.
    Barker RA; Barrett J; Mason SL; Björklund A
    Lancet Neurol; 2013 Jan; 12(1):84-91. PubMed ID: 23237903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.